creased susceptibility to imipenem (IPM) and meropenem (MEM) (inhibition zone range, 16 to 21 mm), while 4 (consecutive) isolates were considered fully resistant to both ( Table  1 ). Independently of their categorization, pulsed-field gel electrophoresis (PFGE) profiles using 20 U/plug SpeI nuclease (NEB) were identical after standard resolution (4) .
These 18 isolates were positive when screened for the class 1 integrase gene and rendered a unique fragment corresponding to the variable region of class 1 integrons, in which imp-13 was the first cassette, followed downstream by an aminoglycoside-modifying enzyme-coding gene, aacA4 (AM931299), 99% identical to that already deposited for Tn5051 (5, 9) .
Because a difference in final carbapenem resistance could be due to different mechanisms, including differential ␤-lactamase content and expression, crude extracts were examined after analytical isoelectrofocusing, detecting enzymatic activity with an iodometry-based overlay system (8); no differences could be seen between both groups of isolates, and no suggestion for any other acquired ␤-lactamase or overexpression of the chromosomal AmpC could be inferred. No significant difference could be found between both groups of isolates concerning spectrophotometric enzymatic activity (EA), expressed as "total" ␤-lactamase activity (using cephalothin [CEF] as a reporter), and carbapenemase activity (using imipenem as reporter). EA for cephalothin (EA CEF ) (U/mg protein) for IPMresistant isolates and IPM-susceptible isolates were (1.7 Ϯ 0.3) ϫ 10 Ϫ7 and (2.2 Ϯ 0.7) ϫ 10 Ϫ7 , respectively. EA for IPM (EA IPM ) (U/mg protein) were (2.7 Ϯ 0.6) ϫ 10 Ϫ07 and (4.2 Ϯ 2.0) ϫ 10 Ϫ7 for resistant and susceptible isolates, respectively. Hydrolysis of imipenem relative to cephalothin (AE IPM /AE CEF ) was 1.5 versus 1.8 in the resistant and susceptible groups, respectively, suggesting there is no difference in the level of expression of carbapenemases between IPM-resistant and IPM-susceptible isolates.
Resistant isolates also lacked a 46-kDa band in outer membrane protein (OMP) profiles (assumed as OprD) (1, 2, 7) .
In vitro analysis for the presence of a high-level resistance subpopulation in two carbapenem-susceptible (IMP-13 producing) isolates (isolates 3 and 7) showed that both MEM and IPM at 16 g/ml could select fully resistant subpopulations at frequencies ranging from 2 ϫ 10 Ϫ8 to 1.6 ϫ 10 Ϫ7 from overnight cultures when cultured on antibiotic-containing agar plates. Independently of the selecting antibiotic, they displayed resistance to both carbapenems. Not a single colony could be obtained by single-step selection from reference strains (ATCC 9027) or clinical isolates without IMP-13 at this concentration.
Mortality among patients with IMP-13-producing (IPM-susceptible) P. aeruginosa infections treated with IPM alone or in combination was 5/8. As this analysis is retrospective, whether subpopulations of fully resistant microorganisms that resulted in treatment failures may have also emerged in those patients (as actually occurs in vitro) cannot be ruled out.
We suggest MBL producers with MICs in the susceptible range should be clearly reported (categorized) differently, indicating the discordance between susceptibility and the presence of a resistance marker, even if their resistance levels do not anticipate therapeutic failure. This categorization would help to redefine the current knowledge on the epidemiological analysis comparing the evolution of patients infected by microorganisms classified as susceptible to carbapenems, but which prove to be IMP producers. Furthermore, this approach may contribute by providing data for discussing if, eventually, the presence of this associated resistance mechanism should modify current CLSI breakpoints (3).
